Orchestra BioMed(OBIO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Orchestra BioMed
OBIO.US
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
1.092 T
OBIO.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking77/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-189.24%E
    • Profit Margin-166.96%E
    • Gross Margin70.91%A
  • Growth ScoreA
    • Revenue YoY1033.89%A
    • Net Profit YoY17.18%B
    • Total Assets YoY70.46%A
    • Net Assets YoY202.34%A
  • Cash ScoreB
    • Cash Flow Margin99.25%C
    • OCF YoY1033.89%A
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreC
    • Gearing Ratio49.37%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

    Market Beat·
    US
    OBIO
    +0.50%
    US
    SBIO
    -1.24%
    US
    PBE
    +0.11%
    Market Beat·
    US
    OBIO
    +0.50%
    US
    SBIO
    -1.24%
    US
    PBE
    +0.11%

    Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | OBIO Stock News

    StockTitan·
    US
    OBIO
    +0.50%
    US
    PBE
    +0.11%
    US
    LABU
    -2.35%
    StockTitan·
    US
    OBIO
    +0.50%
    US
    PBE
    +0.11%
    US
    LABU
    -2.35%

    Orchestra Gains on $20M Buy-in from Medtronic

    Baystreet·
    US
    OBIO
    +0.50%
    US
    MDT
    +1.63%
    US
    BIB
    +0.05%
    Baystreet·
    US
    OBIO
    +0.50%
    US
    MDT
    +1.63%
    US
    BIB
    +0.05%

    Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 | OBIO Stock News

    StockTitan·
    US
    OBIO
    +0.50%
    US
    LABU
    -2.35%
    US
    SBIO
    -1.24%
    StockTitan·
    US
    OBIO
    +0.50%
    US
    LABU
    -2.35%
    US
    SBIO
    -1.24%
    © 2026 Longbridge｜Disclaimer